Society for Immunotherapy of Cancer (SITC) Cancer Immunotherapy Guidelines are a collection of consensus statements developed by experts in the treatment of specific types of cancer. Each consensus statement provides key indicators to help practicing oncologists determine when and how to best use immunotherapy to treat their patients.
In response to the ever-growing demand for expert advice on the optimal use of immunotherapy treatments, our Cancer Immunotherapy Guidelines Task Forces have developed consensus statements for genitourinary malignancies (renal and prostate carcinoma) and hematologic malignancies (multiple myeloma, lymphoma and acute leukemia). An update of the melanoma consensus statement and new guidelines for bladder and lung cancers are also underway.
Click here for a complete listing of the guidelines and links to view.
SITC is the first and only organization dedicated to cancer immunotherapy to be accepted as a formal member of the Commission on Cancer (CoC), a program of the American College of Surgeons.
The CoC is the nation’s leading accreditation body for cancer care and has established a strong partnership approach to defining and measuring quality as it relates to managing patients with cancer. Today, more than 80 percent of Americans with cancer will seek treatment at a CoC accredited facility.
SITC represents leaders of the field of cancer immunotherapy, to help establish and implement immunotherapy at CoC-accredited institutions and develop mechanisms for collecting data and educating healthcare providers on the optimal way to deliver immunotherapy. SITC Immediate Past President, Howard Kaufman, MD, FACS, of the Rutgers Cancer Institute of New Jersey, serves as SITC’s official liaison to the Commission.
SITC has been a key collaborator in the development of the Foundation for the Accreditation of Cellular Therapy (FACT) Standards for Immune Effector Cell Administration.Marcela Maus, MD, PhD of Harvard Medical School serves as SITC’s official liaison to the FACT CAR-T Cell Task Force.
SITC provided formal comments to the FACT draft of the 1st edition FACT Standards for Immune Effector Cell Administration. These standards are intended to promote quality in the administration of immune effector cells and will be incorporated into a voluntary FACT accreditation in this field.
Click here to download "Standards for Immune Effector Cell Administration".
It was great seeing old friends again and meeting new ones at the 32 nd Annual Meeting & Pre-Conference Programs in National Harbor! We appreciate all who joined SITC for our most successful Annual Meeting yet and hope you had a great time learning, ...
The cited 2017 case report states " The restoration of the cellular immune response against tumor cells through PD-1 blockade and CRLA-4 blockade have recently been shown to be associated with increased survival in metastatic RCC developed from native ...
This is an interesting subject to me since a few years back we published a study in the American Journal of Transplantation that showed blocking mTOR with a low dose of rapamycin enhanced anti-tumor activity while suppressed allogeneic response in ...
Thanks for the comments. He is to start TKI, but is also asking about other ideas. There are multiple non-Oncologist physicians in family who are feeding him questions and idea. I'm sure I won't be his only opinion. Bill ------------------------------ ...
I agree with Drs. Rini and Atkins, I would use TKIs, which can often control disease for many years. I did, however, want to highlight a recent case report in NEJM whereby prophylactic tacrolimus and glucocorticoid therapy was given to successfully prevent ...
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: firstname.lastname@example.org